首页> 外文期刊>BMJ Open >Comparison of Enteral versus Intravenous Potassium Supplementation in hypokalaemia in postcardiac surgery paediatric cardiac intensive care patients: prospective open label randomised control trial (EIPS)
【24h】

Comparison of Enteral versus Intravenous Potassium Supplementation in hypokalaemia in postcardiac surgery paediatric cardiac intensive care patients: prospective open label randomised control trial (EIPS)

机译:明信片手术小儿心脏重症监护患者低钾血症肠内和静脉内补钾的比较:前瞻性开放标签随机对照试验(EIPS)

获取原文
           

摘要

Background Hypokalaemia is frequently encountered in the daily clinical practices of a paediatric cardiac intensive care unit (PCICU). It is a strong independent predictor of mortality in patients with heart failure. Thus, prompt potassium replacement therapy holds pivotal importance in therapy for hypokalaemia. Although intravenous potassium replacement (IVPR) in hypokalaemia is the preferred route in most intensive care settings, it is associated with known safety risks and can lead to arrhythmias, cardiac arrest and death if inappropriately administered. Enteral potassium replacement (EPR), with its superior safety profile, may be a better alternative to IVPR. Outcome Primary outcome To compare the efficacy EPR and IVPR for treatment of hypokalaemia. Secondary outcome measures include a comparison of adverse effects (hyperkalaemia, diarrhoea, gastrointestinal bleeds, nausea and vomiting) after EPR and IVPR and a comparison of the number of dose/s required to achieve resolution of hypokalaemia for each episode of hypokalaemia. Methods and analysis The Enteral Versus Intravenous Potassium Supplementation trial is designed as a randomised, controlled, non-blinded trial with two arms. Intervention arms will be block randomised on alternate weeks for IVPR and EPR. Recruited patients will receive treatment accordingly. For analysis, the percentage change in serum potassium levels in mEq/L after each event of potassium replacement in both arms will be used as an end point to compare the efficacy EPR and IVPR for treatment of hypokalaemia. Study setting The study will be conducted at the PCICU at the Aga Khan University Hospital, Karachi. Ethics and dissemination This study has been approved by the Ethics Review Committee and Clinical Trials Unit at The Aga Khan University with respect to scientific content and compliance with applicable research and human subjects regulations. Trial registration number This trial is registered at Clinical Trials.Gov. Registration number: NCT02015962.
机译:背景低钾血症在小儿心脏重症监护病房(PCICU)的日常临床实践中经常遇到。它是心力衰竭患者死亡率的强有力的独立预测因子。因此,迅速的钾替代疗法在低钾血症的治疗中具有至关重要的作用。尽管低钾血症中的静脉补钾(IVPR)在大多数重症监护环境中是首选的途径,但与已知的安全风险有关,如果使用不当,可能导致心律不齐,心脏骤停和死亡。肠内补钾(EPR)具有出色的安全性,可能是IVPR的更好替代方案。结局主要结局比较EPR和IVPR治疗低钾血症的疗效。次要结果指标包括比较EPR和IVPR后的不良反应(高钾血症,腹泻,胃肠道出血,恶心和呕吐),并比较每次低钾血症发作所需的低剂量剂量。方法和分析肠内和静脉内补钾试验设计为具有两个臂的随机,对照,无盲试验。 IVPR和EPR的干预组将隔周随机分组。被招募的患者将接受相应的治疗。为了进行分析,将两次手臂每次更换钾事件后以mEq / L计的血清钾水平变化百分比作为终点,以比较EPR和IVPR治疗低钾血症的疗效。研究设置该研究将在卡拉奇阿迦汗大学医院的PCICU中进行。伦理与传播本研究已获阿迦汗大学伦理审查委员会和临床试验部门批准,涉及科学内容以及对适用研究和人类受试者法规的遵守情况。试验注册号该试验在Clinical Trials.Gov中注册。注册号:NCT02015962。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号